CLINICAL RESPONSE TO DRUGS METABOLIZED BY CYTOCHROME P450 FAMILY ENZYMES: CLINICAL EXOME PANEL (Sec. & CNVs) – 8 genes
Delivery time
3-4 weeks
Sample
Blood
The panel focused on drugs metabolized by cytochrome P450 enzymes studies the main genetic variants that determine an individual's metabolic capacity to respond to multiple clinically used drugs. These enzymes are responsible for the biotransformation of more than 70% of prescribed medications, including antidepressants, antipsychotics, opioids, anticoagulants, anti-inflammatories, antiepileptics, beta-blockers, antiplatelet agents, statins, and chemotherapeutic agents. Identifying polymorphisms in genes such as CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, SLCO1B1, and VKORC1 allows for dose adjustments, prediction of therapeutic response, and minimization of serious adverse effects, thus optimizing pharmacological treatment in a wide variety of pathologies.
Other tests
Exome panel analysis of 29 genes - idiopathic pulmonary fibrosis and surfactant protein deficiency
990,00€
511 gene analysis - epilepsy (using exome sequencing)
1.495,00€
Exome analysis of AGXT, GRHPR, and HOGA1 genes - primary hyperoxaluria
690,00€